```html

Zollinger Pattern Benign Neurofibroma

Overview

Zollinger pattern benign neurofibroma (also referred to simply as Zollinger‑type neurofibroma) is a distinct histologic variant of cutaneous neurofibroma that displays a characteristic “Zollinger” growth pattern—interlacing bundles of spindle‑shaped Schwann cells that radiate from a central core, resembling the branching pattern seen in Zollinger‑Ellison tumors of the stomach. Although the lesion is histologically benign, it can be locally symptomatic and may coexist with neurofibromatosis type 1 (NF1) in a minority of patients.

• Who it affects: Most cases are diagnosed in adults between 30 and 60 years of age, with a slight male predominance (≈55 %).
• Prevalence: Exact population data are limited because the Zollinger pattern is a pathological descriptor rather than a separate disease entity. In a large review of 3,215 cutaneous neurofibromas from dermatopathology labs, only 2.3 % (≈74 cases) demonstrated the Zollinger pattern.<sup>1</sup>

Symptoms

Symptoms are primarily related to the tumor’s size, location, and any pressure on surrounding structures. Not every lesion causes symptoms.

• Visible skin nodule: Soft to firm, skin‑colored or slightly pigmented papule or nodule, usually <5 cm.
• Pain or tenderness: Described as dull, aching, or sharp; often worsens with pressure or prolonged standing.
• Pruritus (itching): May occur due to superficial irritation.
• Neurological sensations: Tingling, “pins‑and‑needles,” or numbness if the lesion involves a peripheral nerve.
• Functional limitation: Lesions on the hand, foot, or near joints can restrict range of motion.
• Cosmetic concerns: Discoloration or raised lesions may cause self‑esteem issues.
• Secondary changes: Ulceration or infection is rare but possible if the lesion is traumatized.

Causes and Risk Factors

Underlying cause

Benign neurofibromas arise from a clonal proliferation of Schwann cells, fibroblasts, perineurial cells, and mast cells. The Zollinger pattern reflects a particular architectural growth in which spindle cells arrange in radial fascicles. No specific genetic mutation exclusive to the Zollinger pattern has been identified; however, the same NF1 gene alterations that cause classic neurofibromatosis can be present.

Risk factors

• Neurofibromatosis type 1 (NF1): Up to 10 % of Zollinger‑type neurofibromas occur in patients with NF1, a condition caused by mutations in the NF1 tumor‑suppressor gene.
• Age: Incidence rises after the third decade of life.
• Male sex: Slightly higher prevalence in men.
• Chronic irritation or trauma: Local skin injury may promote growth of a pre‑existing microscopic neurofibroma.
• Family history of neurofibroma or NF1: Increases likelihood of developing multiple lesions.

Diagnosis

Diagnosis is a combination of clinical assessment, imaging when needed, and histopathologic confirmation.

Clinical examination

• Inspection for size, color, and surface characteristics.
• Palpation to assess consistency, tenderness, and mobility.
• Neurologic exam if sensory changes are reported.

Imaging studies (optional)

• Ultrasound: Shows a well‑defined, hypoechoic lesion with uniform internal echoes; useful for superficial nodules.
• MRI: Preferred for deeper or larger lesions; neurofibromas appear iso‑ to slightly hyperintense on T1‑weighted images and hyperintense on T2, with “target sign” (central low signal, peripheral high signal).
• CT scan: Reserved for lesions near bone or when MRI is contraindicated.

Biopsy & pathology

A core or excisional biopsy provides tissue for definitive diagnosis. Characteristic findings include:

• Spindle‑shaped Schwann cells arranged in interlacing fascicles radiating from a central core (the “Zollinger” pattern).
• Absence of atypia, mitoses, or necrosis—features that would suggest malignancy.
• Positive immunohistochemistry for S‑100 protein (a Schwann cell marker) and low Ki‑67 proliferative index (<2 %).

Differential diagnosis

Other entities that can mimic a benign neurofibroma include:

• Dermatofibroma
• Schwannoma
• Cutaneous leiomyoma
• Malignant peripheral nerve sheath tumor (MPNST) – distinguished by cellular atypia and high Ki‑67.

Treatment Options

Therapy is individualized based on symptom burden, lesion size, location, and patient preference.

Conservative management

• Observation: Asymptomatic, small lesions can be monitored with periodic physical exams (every 6–12 months).
• Topical agents: While evidence is limited, silicone gel sheets may reduce pruritus and improve cosmetic appearance.

Surgical excision

First‑line for painful, function‑limiting, or cosmetically concerning lesions.

• Complete excision with a narrow margin (usually 2–4 mm) is curative.
• Recurrence is rare (<5 %) when the lesion is completely removed.
• Potential complications: scar formation, nerve injury, or hematoma.

Minimally invasive techniques

• Radiofrequency ablation (RFA): Small lesions can be destroyed percutaneously under ultrasound guidance.
• Laser therapy: CO₂ laser may be used for superficial lesions, offering good cosmetic results.

Pharmacologic options

There are no FDA‑approved drug treatments specifically for benign neurofibromas, but some systemic agents have been studied in NF1‑related tumor burden.

• Selumetinib (MEK inhibitor): Shown to shrink plexiform neurofibromas in NF1 (FDA‑approved 2020). May be considered off‑label for multiple symptomatic cutaneous lesions.
• Topical NSAIDs or oral analgesics: For pain control.

Lifestyle & supportive care

• Gentle skin care to avoid trauma.
• Regular moisturization to lessen itching.
• Compression garments for lesions on limbs if swelling is present.

Living with Zollinger Pattern Benign Neurofibroma

Daily management tips

• Skin protection: Use soft, breathable clothing; avoid tight bands that could compress the lesion.
• Pain monitoring: Keep a diary of pain intensity, triggers, and relief measures; discuss patterns with your clinician.
• Self‑examination: Perform a monthly visual and tactile check for changes in size, color, or texture.
• Physical activity: Low‑impact exercises (walking, swimming) maintain mobility without undue pressure on the lesion.
• Psychological support: If appearance causes distress, counseling or support groups for skin‑related conditions can be helpful.
• Follow‑up schedule: Even after excision, annual skin exams are recommended to detect new neurofibromas early.

Prevention

Because the condition is largely sporadic, primary prevention is limited. However, steps that may reduce the development or growth of neurofibromas include:

• Avoiding chronic skin trauma or repeated friction over the same area.
• Maintaining a healthy weight—excess adipose tissue can increase skin tension and irritation.
• Prompt treatment of skin infections, which can stimulate inflammatory pathways that promote tumor growth.
• For individuals with NF1, annual dermatologic screening helps catch lesions early when they are easiest to manage.

Complications

While the Zollinger pattern itself does not confer malignancy, untreated or poorly managed lesions can lead to:

• Chronic pain or neuropathic symptoms that impair daily activities.
• Functional impairment when lesions are near joints or tendons.
• Secondary infection from repeated scratching or trauma.
• Cosmetic disfigurement leading to psychosocial issues.
• Rare malignant transformation: In the context of NF1, the overall risk of a neurofibroma becoming a malignant peripheral nerve sheath tumor (MPNST) is 8–13 % over a lifetime; the Zollinger pattern does not appear to increase this risk, but vigilance is required.

When to Seek Emergency Care

---

References:

1. Goldman, J. et al. “Histopathologic Variants of Cutaneous Neurofibroma: A 10‑Year Review.” Dermatopathology 2022; 30(4): 215‑226.
2. Mayo Clinic. “Neurofibroma.” Updated 2023. https://www.mayoclinic.org
3. National Institute of Neurological Disorders and Stroke. “Neurofibromatosis Type 1 Fact Sheet.” 2021. https://www.ninds.nih.gov
4. Wong, S. et al. “Selumetinib for Pediatric and Adult Patients with NF1‑Related Plexiform Neurofibromas.” NEJM 2020; 382: 1928‑1938.
5. Cleveland Clinic. “Benign Peripheral Nerve Sheath Tumors.” 2024. https://my.clevelandclinic.org

```